ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2017

Hyper Ferritinemia Suggests a High Frequency Of Macrophage Activation Syndrome In a Large Adult Severe Sepsis Cohort: A Role For Anakinra?

Bita Shakoory1, Joseph A. Carcillo2 and Steven Opal3, 1Medicine/Rheumatology, Temple University, Philadelphia, PA, 2Pediatrics, University of Pittsburg Medical Center, Pittsburgh, PA, 3Medicine, Brown University, Providence, RI

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: macrophage activation syndrome

  • Tweet
  • Email
  • Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases II: Miscellaneous Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Inreased ferritin levels are protective during infection whereas but very very high level are associated with MAS in rheumatologic disease cTo determine frequency of macrophage activation syndrome (MAS) in a sepsis cohort defined by using ferritin level (> 2,000), and to compare outcome, organ involvement and response to anakinra in sepsis across levels of Ferritinemia. 

Methods:

Remaining sera and data from “interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial” (Opal, et. al. Crit Care Med. 1997 Jul;25(7):1115-24.) was analysed. Ferritin was measured in the remaining sera of de-identified subjects from this study (levels beyond 6,000 were not further diluted). Subgroups were defined based on serum ferritin ranges (0-499, 500-999, 1000-1999, above 2000 μg/L). Post hoc statistical analysis included: descriptive statistics, rank test, ANOVA, Cox regression. 

Results:

Sera and data were available for ferritin measurement in 120/756 original study cohort (ages 22-85; 41.6% women). Demographics and  28-day outcome with or without anakinra in the ferritin subgroups are shown in Table. The Ferritin subgroup 500-999 had higher 28 day survival than other subgroups (18/21, 85.7%)(p < .05?), which was decreased with anakinra (100% alive in placebo vs. 82.4% with anakinra). The Ferritin subgroup >2000 (24/29, 24.2%) showed lower 28-day survival, which was increased with anakinra (40% with placebo vs. 57.9% with anakinra).  

Conclusion:

As hypothesized, an increased Ferritin 500-1000 showed  a  protective inflammatory response in adult severe sepsis patients, whereasvery high Ferritin levels > 2,000 μg/L may signify immune dysregulation and concurrent MAS ( 25% of adult severe sepsis patients). Given the high mortality of unrecognized MAS in adults with rheumatic diseases (up to 64% reported) further stuies are warranted both evaluating ferritin in the diagnosis of, and anakinra in the treatment of  severe sepsis associated MAS (Ferritin > 2,000)

Ferritin Range

Group N (%)

(Total 120)

Age Range 

Woman (%)

28 Day Alive

28 Day Alive

Anakinra

Placebo

0-499

42 (35.0)

25-85

18/42 (42.9)

27 (64.3)

17/27 (62.9)

10/15 (67.7)

500-999

21 (17.5)

22-83

7/21 (33.3)

18 (85.7)

14/17 (82.4)

4/4 (100)

1000-1999

28 (23.3)

22-81

15/28 (53.6)

18 (64.3)

16/25 (64.0)

2/3 (67.7)

>2000

29 (24.2)

28-76

10/29 (34.5)

15 (51.8)

11/19 (57.9)

4/10 (40)


Disclosure:

B. Shakoory,
None;

J. A. Carcillo,
None;

S. Opal,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hyper-ferritinemia-suggests-a-high-frequency-of-macrophage-activation-syndrome-in-a-large-adult-severe-sepsis-cohort-a-role-for-anakinra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology